Ex Vivo Expansion of Umbilical Cord Blood Hematopoietic Stem Cells on Collagen- Fibronectin Coated Electrospun Nano Scaffold
Authors
Abstract:
Background and Objective: Umbilical Cord blood (UCB) hematopoietic stem cell (HSC) transplantation is a therapeutic approach for the treatment of malignant and non-malignant hematologic disorders due to ease of collection, lack of risk for donors and lower levels of infection. Moreover, it is considered a good alternative for bone marrow HSC transplantation. The main limitation of their use is insufficient amount of HSCs due to low volume of blood collected from umbilical cord. A possible solution to overcome this limitation may be the in vitro expansion of these cells on 3D nanofiber scaffolds, with the goal of natural niche’s topography and chemistry mimicking. Materials and Methods: In this study, MACS isolated CD133+ cells were confirmed via flow cytometry and then cultured in three conditions: 2-dimensional culture (2D), 3D PLLA scaffold and collagen-fibronectin coated PLLA scaffold. : Comparison between three aforementioned groups showed that collagen-fibronectin coated scaffold had the highest expansion level CD133+ cells, while also having the highest clonogenic capacity and biocompatibility. Conclusion: The results of this study showed that the protein coating of 3D PLLA scaffold with collagen-fibronectin provides a suitable system for the expansion of cells with minimal differentiation in vitro.
similar resources
Nanofiber Expansion of Umbilical Cord Blood Hematopoietic Stem Cells
Background The aim of this study was the ex vivo expansion of Umbilical Cord Blood hematopoietic stem cells on biocompatible nanofiber scaffolds. Materials and Methods CD133+ hematopoietic stem cells were separated from umbilical cord blood using MidiMacs (positive selection) system by means of monocolonal antibody CD133 (microbeads) subsequently, flowcytometry method was done to asses...
full textnanofiber expansion of umbilical cord blood hematopoietic stem cells
background the aim of this study was the ex vivo expansion of umbilical cord blood hematopoietic stem cells on biocompatible nanofiber scaffolds. materials and methods cd133+ hematopoietic stem cells were separated from umbilical cord blood using midimacs (positive selection) system by means of monocolonal antibody cd133 (microbeads) subsequently, flowcytometry method was done to assess the pur...
full textEx Vivo Expansion of Hematopoietic Stem and Progenitor Cells from Umbilical Cord Blood
Transplantation of umbilical cord blood cells is currently widely used in modern cell therapy. However, the limited number of hematopoietic stem and progenitor cells (HSPCs) and prolonged time of recovery after the transplantation are significant limitations in the use of cord blood. Ex vivo expansion with various cytokine combinations is one of the most common approaches for increasing the num...
full textexpansion of human cord blood hematopoietic stem/progenitor cells in three-dimensional nanoscaffold coated with fibronectin.
allogeneic hematopoietic stem cell transplantation is used in the treatment of patients suffering from hematologic and non-hematologic disorders, but the application is limited by the identification of a suitable donor. umbilical cord blood (ucb) is an alternative source of hematopoietic stem cell (hsc) transplantation. despite all advantages, the limited cell dose is one of the major obstacle...
full textتکثیر سلولهای بنیادی خونساز خون بندناف بر روی بسترهای نانوالیاف زیست سازگار: گزارش کوتاه
Background: Hematopoietic stem cell transplantation (HSCT) is a therapeutic approach in treatment of hematologic malignancies and incompatibility of bone marrow. Umbilical cord blood (UCB) known as an alternative for hematopoietic stem/ progenitor cells (HPSC) for in allogenic transplantation. The main hindrance in application of HPSC derived from umbilical cord blood is the low volume of colle...
full textتاثیر آشیانههای جفتی شبیهسازی شده با داربست پلی لاکتیک اسید در تکثیر سلولهای بنیادی خونساز مشتق از بافت جفت انسانی
Background and Objective: Nowadays, although umbilical cord blood is a commonly used source of hematopoietic stem cell, its low frequency of these cells is the main factor limiting its clinical application. The transplantation of hematopoietic stem cells derived from placenta tissue along with umbilical cord blood cells of the same sample may be an appropriate approach to solve this problem. In...
full textMy Resources
Journal title
volume 26 issue 117
pages 32- 43
publication date 2018-09
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023